MedTrace Logo

Safety and Efficacy of Changing to DuoTrav From Prior Therapy

NCT01230736 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2016-11-21

No results posted yet for this study

Summary

The purpose of this study to assess the safety and efficacy of changing to DuoTrav® from prior bimatoprost 0.03%/timolol 0.5% (used concomitantly or in a fixed combination) pharmacotherapy in uncontrolled patients with open-angle glaucoma or ocular hypertension.

Conditions

Interventions

DRUG

Travoprost 0.004%/Timolol 0.5% Fixed Combination eye drops solution (Duotrav®)

One drop in study eye(s) once daily for 8 weeks

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01230736 on ClinicalTrials.gov